B of A Securities Maintains Underperform on CureVac, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains an 'Underperform' rating on CureVac (NASDAQ:CVAC) and has lowered the price target from $10 to $8.
August 21, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained an 'Underperform' rating on CureVac and lowered the price target from $10 to $8.
The 'Underperform' rating maintained by B of A Securities and the lowering of the price target from $10 to $8 indicates a negative outlook for CureVac. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100